期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 53, 期 5, 页码 1766-1771出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01410-08
关键词
-
资金
- INSERM, France
- Ministere de l'Education Nationale et de la Recherche [UPRES-EA3539]
- Universite Paris XI, France
- European Community DRESP2 [LSHM-CT-2005-018705]
- Ministerio de Educacion y Ciencia from Spain [2007/029]
The characterization of AmpC-type beta-lactamases was performed in a collection of 32 clinical Pseudomonas aeruginosa isolates with intermediate susceptibility or resistance to imipenem and ceftazidime. Twenty-one out of those 32 isolates overexpressed AmpC beta-lactamase, and the MICs of ceftazidime and imipenem were reduced after cloxacillin addition. Cloning and sequencing identified 10 AmpC beta-lactamase variants. Reduced susceptibility to imipenem, ceftazidime, and cefepime was observed only with recombinant P. aeruginosa strains expressing an AmpC beta-lactamase that had an alanine residue at position 105. The catalytic efficiencies (k(cat)/K-m) of the AmpC variants possessing this residue were increased against oxyiminocephalosporins and imipenem. In addition, we show here that those AmpC variants constitute a favorable background for the in vitro selection of imipenem-resistant strains. This report identified a novel resistance mechanism that may contribute to imipenem resistance in P. aeruginosa.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据